DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Iratumumab
Iratumumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Tanibirumab (CUI C3490677) Add to Cart
(12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
Download of These Slides, Please Direct Your Browser to the Following Web Address
Ep 3321281 A1
Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It
Inhibitors of a Disintegrin and Metalloproteinases-10 Reduce
INN Working Document 05.179 Update 2011
Therapeutic Antibody
Stembook 2018.Pdf
INN Working Document 05.179 Update December 2010
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
A61K9/51 (2006.01) — with International Search Report (Art
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Top View
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
Assessment of the Evolution of Cancer Treatment Therapies
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
Irinotecan Hydrochloride 737 Leukin; Fr.: Proleukin; Ger.: Proleukin; Gr.: Proleukin; Hong Kong: Pro- Curs And, Less Commonly, Thrombocytopenia
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
Antibody-Drug Conjugates&Mdash;An Emerging Class of Cancer Treatment
Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Com(2010)0397
WO 2017/096163 Al 8 June 2017 (08.06.2017) W P O P C T
Utilizing CD30 Expression As a Rational Target for Therapy of Lymphoma Won Seog Kim from New Development in Hematology and Oncology in 2011 Guangzhou, China
The Honorable Shara Aranoff Chairman United States International Trade Commission 500 E Street, S.W. Washington, DC 20436 Dear C
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Impact of Endocytosis Mechanisms for the Receptors Targeted By
Medicines & Vaccines in Development for Cancer
Ep 3088005 A1
WO 2015/036956 Al 19 March 2015 (19.03.2015) P O P C T
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
Understanding CD30 Biology and Therapeutic Targeting: a Historical Perspective Providing Insight Into Future Directions